NEWS YOU CAN USE
Medical Innovation That Wow Us
Tahareinu leadership stays updated on reproductive health medicine by attending global conferences and keeping the latest research. Read this month's updates below.
Fibroids: Solutions without Surgery
Uterine fibroid pain can be debilitating for many women. At long last, there are now non-surgical options for reducing symptoms.
1. Hormonal pills are available for heavy menstrual bleeding (HMB) associated with fibroids. Two products are on the market - Oriahnn, available now, and YSelty, still in clinical trials. Both are pills whose ingredients scale down certain hormones to reduce menstrual bleeding, in turn reducing fibroid pain.
2. A new ultrasound device shrinks fibroids. Sonata's new innovation uses radiofrequency energy to reduce the size of uterine fibroids, limiting their problematic effects.
Read the latest on new contraceptions below.
Lower Estrogen Methods
Two new contraceptives offer novel low estrogen levels, reducing risks of physical and mental side effects. The products are Twirla, a patch worn for 21 consecutive days per cycle, and Nextellis, a 28-day combination pill.
Liletta is a new hormonal IUS (intrauterine system, or IUS, otherwise
known as an IUD, intrauterine device). Its advantages are that it is smaller in size and flexible, able to mold better within the body. For use up to six years.
Launching a totally new concept, Phexxi is a vaginal suppository contraceptive which is not a spermicide. Instead, Phexxi works to maintain vaginal pH, reducing sperm mobility to lower the chance of conception by 96% on average.
Fertility and POI (Premature Ovarian Insufficiency)
Some women experience a type of early menopause whereby their eggs are unusable for conception during childbearing age. Two procedures are now available to combat this problem.
1) IVA, or in-vitro activation, can reverse egg insufficiency. The procedure involves removing the eggs, freezing them, treating them and then grafting them back onto the woman. From there, these renewed eggs are extracted for use in IVF.
2) Platelet Rich Plasma (PRP) Ovarian Rejuvenation. With this process, a woman’s own PRP is injected into her ovaries in order to stimulate and activate her eggs with growth-factor-rich proteins and relevant stem-cell properties (chemoattractants).
While these two procedures are obviously quite involved, nonetheless they may be the saving grace for some couples. Call the Tahareinu hotline for more information.
COVID-19 Inoculation Update
Tahareinu is consulted routinely about the Covid-19 inoculations. It's a controversial topic and here's the latest info.
For women receiving the Pfizer or Moderna Covid-19 symptom-reducing immunizations, major medical bodies have released studies recently denouncing direct correlation with infertility or miscarrage in the short term. No long term studies on overall health or fertility are available because the products were permitted by the FDA under emergency use authorization (EUA) only six months ago.
For couples undergoing IVF, a slight reduction in success rates was noted by an Israeli study for up to three months after completing the second dose of the Pfizer inoculations. Therefore, especially for couples whose embryo reserves are low, Tahareinu recommends waiting until at least three months after the injections before starting or resuming fertility treatments.